Truist analyst Joon Lee raised the firm’s price target on Axsome Therapeutics (AXSM) to $190 from $180 and keeps a Buy rating on the shares. The company disclosed approval of Symbravo – AXS-07 – for migraine with broad label and hosted a webcast with Dr. Tepper, a well known migraine key opinion leader, and the subsequent commentaries are “highly positive” and consistent with totality of clinical data from Phase 3 INTERCEPT and MOMENTUM trials, the analyst tells investors in a research note.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXSM:
- Axsome Therapeutics price target raised to $132 from $116 at Baird
- Axsome Therapeutics hosts SYMBRAVO FDA approval investor event
- Axsome Therapeutics price target raised to $190 from $180 at H.C. Wainwright
- Axsome Therapeutics announces FDA approval of Symbravo
- Axsome Therapeutics price target raised to $155 from $125 at TD Cowen